SB 216763 |
Katalog-Nr.GC10463 |
SB 216763 stands out as a powerful, selective, and ATP-competitive inhibitor of GSK-3, effectively targeting both GSK-3α and GSK-3β with an impressive IC50 of 34.3 nM[1-3].
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 280744-09-4
Sample solution is provided at 25 µL, 10mM.
SB 216763 stands out as a powerful, selective, and ATP-competitive inhibitor of GSK-3, effectively targeting both GSK-3α and GSK-3β with an impressive IC50 of 34.3 nM[1-3].
SB 216763(1-20 µM; 24 hours) induces β-catenin mediated-transcription in a dose-dependent manner. Besides, SB 216763(10, 15 and 20 µM) can maintain mouse embryonic stem cells (mESCs) in a pluripotent state in the absence of exogenous leukemia inhibitory factor (LIF) when cultured on mouse embryonic fibroblasts (MEFs) [4]. SB 216763 enhances neurogenesis but does not alter cell cycle exit or cell survival[5].
SB 216763(1-1.5 mg/kg/day;4weeks;s.c) was able to reverse the increased expression levels of molecular markers of inflammation and fibrosis in the heart and kidneys induced by aldosterone (Aldo) injection. Additionally, SB 216763 effectively suppressed cardiac and renal inflammatory cytokine levels, including TNF-a, IL-1β, and MCP-1[6]. SB 216763(10 mg/kg;i.p;3weeks) can reduce delayed gastric emptying (DGE) in high-fat diet (HFD)-induced obese/Type 2 diabetes (T2D) female mice[7]. Pretreatment with SB 216763 (2.5-5 mg/kg, i.p.) prior to amphetamine (2 mg/kg, i.p.) significantly reduced amphetamineinduced ambulation and stereotypy[8].
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *